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TRANSLATIONAL RELEVANCE 
 
One of the most pressing obstacles for immunotherapy for cancer is the 
development of rational based combination therapies since monotherapies only 
allow responses in a limited patient population. Herein we demonstrated the 
bench-to-bedside development of Fibroblast Activation Protein (FAP)-specific 
CAR redirected T cells. For optimal testing of redirected T cells, a humanized 
mouse model containing most components of the human immune system was 
developed. CARs with distinct co-stimulatory domains were designed and 
tested.  We identified a particular CAR with a mutated CD28 signaling domain 
that provided enhanced antigen-specific proliferation, increased T-cell 
metabolism, activation and redirected T cell mediated tumor control in 
combination with PD-1 blockade in vivo. Additionally, we used these data to 
launch a first-in-human clinical trial injecting FAP-specific redirected T cells in the 
pleural effusion of patients with malignant pleural mesothelioma. Our pre-
clinical and clinical data lay the groundwork for further testing of FAP-specific 
redirected T cells. 
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ABSTRACT 
 
Purpose: Combination therapy of adoptively transferred redirected T cells and 
checkpoint inhibitors aims for higher response rates in tumors poorly responsive 
to immunotherapy like malignant pleural mesothelioma (MPM). Only most 
recently the issue of an optimally active chimeric antigen receptor (CAR) and the 
combination with checkpoint inhibitors is starting to be addressed.  
 
Experimental design: Fibroblast Activation Protein (FAP)-specific CARs with 
different co-stimulatory domains including CD28, -CD28 (lacking lck binding 
moiety) or 4-1BB were established. CAR-T cells were characterized in vitro and 
anti-tumor efficacy was tested in vivo in a humanized mouse model in 
combination with PD-1 blockade. Finally, the -CD28 CAR was tested clinically in 
a MPM patient.  
 
Results: All the three CARs demonstrated FAP-specific functionality in vitro. 
Gene expression data indicated a distinct activity profile for the -CD28 CAR 
including higher expression of genes involved in cell division, glycolysis, fatty acid 
oxidation and oxidative phosphorylation. In vivo, only T cells expressing the -
CD28 CAR in combination with PD-1 blockade controlled tumor growth. When 
injected into the pleural effusion of a MPM patient, the -CD28 CAR could be 
detected for up to 21 days and showed functionality.  
 
Conclusions: Overall, anti-FAP--CD28/CD3 CAR T cells revealed superior in 
vitro functionality, better tumor control in combination with PD-1 blockade in 
humanized mice, and persistence up to 21 days in a MPM patient. Therefore, 
further clinical investigation of this optimized CAR is warranted. 
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INTRODUCTION 
 
Chimeric antigen receptor (CARs) are composed of an antibody derived, target 
antigen specific single-chain variable fragment (scFv) which is linked to T-cell co-
stimulatory domains such as CD28, 4-1BB, ICOS, CD27 or OX40 in addition to the 
T-cell signaling domain CD3 (1). CARs can be designed to recognize tumor 
associated antigens (TAAs) and thereby can be utilized to redirect T cells against 
cancer cells. 
Until now, most remarkable clinical responses have been observed using 
anti-CD19-CARs in hematological malignancies (2). Based on these promising 
results, redirected T cell therapy needs further evaluation, to allow for clinical 
benefit in other malignancies, especially solid tumors. 
Pre-clinical evaluation of redirected T cells often employs immune 
compromised mouse models. These models provide limited understanding of 
the interplay between human tumors and redirected T cells, without depicting 
interactions with other immune system components. Unlike in a human host, 
the transferred T cells cannot benefit from human cytokines like IL-7 and IL-15 
(3). Furthermore, in immune compromised mice adoptive transfer of T cells 
educated outside the mouse host can result in graft-versus-host-disease (GvHD) 
(3). Humanized mouse models overcome some of these limitations and have 
demonstrated to be a powerful model system at least for the study of human 
viruses (4). Using human hematopoietic progenitor cells (HPCs), immune 
compromised mice develop most human lymphocyte and myeloid lineages (5). 
Attributed to the partly developed human immune environment, humanized 
mice can provide a robust host, for blocking or boosting anti-cancer immune 
reactions mediated by adoptively transferred redirected T cells. 
Malignant pleural mesothelioma (MPM) is a disease which cannot be 
cured even at early stages (6). Recently, encouraging data using PD-1 blocking 
antibodies indicated that the immune system can attack MPM and result in 
clinical responses (7,8). However, only a minority of patients responded to PD-1 
blockade. One possible explanation could be the absence of a T-cell repertoire 
that can generate a therapeutic immune response. A potential approach to 
overcome this limitation is transfer of redirected T cells recognizing antigens 
expressed in MPM. Fibroblast Activation Protein (FAP) is expressed in MPM and 
is therefore a potential target antigen (9). We constructed anti-FAP (scFv F19) 
Research. 
on August 20, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 10, 2018; DOI: 10.1158/1078-0432.CCR-17-1788 
 6 
CAR constructs with different co-stimulatory moieties, CD28, -CD28 and 4-1BB 
and tested them in vitro and in a humanized mouse model. The -CD28 CAR 
carries a deletion in the lck binding domain which was initially shown to 
augment anti-tumor responses due to aberrant IL-2 production which was no 
longer available to sustain persistence of Tregs, infiltrating tumors (10).  
Our data indicate that the -CD28 CAR mediates superior in vitro 
functionality, showed enhanced metabolism, activation after cognate antigen 
encounter, and mediated better tumor control in combination with PD-1 
blockade in humanized mice. Based on these findings, the -CD28 CAR was 
further used for a first in-man adoptive transfer of FAP-specific redirected T cells 
in MPM patient. This study provides the rationale for further exploring FAP-
specific -CD28 CAR redirected T cells in patients with MPM and other malignant 
tumours expressing FAP.  
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METHODS 
 
Cell lines 
293T cells were purchased from ATCC (Manassas, VA, USA). HT1080FAP and 
HT1080PA cell lines were generated by stably transfecting HT1080 cells with 
human FAP or mock plasmid, respectively, in addition to the luciferase plasmid, 
as described previously (11). All cell lines were routinely tested and confirmed 
negative for mycoplasma contamination. For details about culturing conditions, 
refer to supplemental notes.  
 
T cell activation with anti-CD3/CD28 
CD3+ T cells isolated from healthy leucocyte concentrate donors were incubated 
with CD3/28 beads at 1:5 bead:cell ratio or anti-CD3 and anti-CD28 antibodies 
(1ug/ml) either supplemented in T cell medium (TCM; RPMI + 2mM L-glutamine 
+ 10% FBS + 50 U/ml penicillin + 50 g/ml streptomycin and 1X NEAA (Non-
essential amino acids solution)) or coated on 24 well plates (Corning). After 48 
hours, the CD3/28 stimulus was removed and cells were incubated in TCM 
supplemented with 200 IU/ml IL-2 (Peprotech, NJ, USA), and 10ng/ml of both IL-
7 and IL-15 (Miltenyi Biotech). Alternatively, cells were labelled with CFSE and 
CFSE dilution assays were performed as described before (12). Phenotypic 
markers were analyzed by flow cytometry at several time points after removal of 
the CD3/28 stimulus. 
 
Generation of CAR constructs and retroviral transduction of T cells 
The single chain variable fragment (scFv) of the FAP-specific CAR (F19) (11) and 
the NY-ESO-1 specific CAR (T1), which serves as control in this study (recognizing 
the HLA-A*02:01/NY-ESO-1157-165 peptide complex) (13) flanked by NCOI and 
BamHI restriction sites, was cloned into the pBullet vector (14), containing a 
human -CH2/CH3 domain of the co-stimulatory domains of either CD28, -
CD28 or 4-1BB, and the CD3 domain (kindly provided by Dr. Hinrich Abken, 
University of Cologne, Germany). The human -CH2/CH3 domain contains a 
modification which reduces binding of the respective CARs to FcγR+ cells (15) 
and thereby minimizes off-target activation. The -CD28 is a modification of the 
CD28 co-stimulatory domain (generated by site directed mutagenesis), which is 
devoid of the lck kinase binding site (10). The resulting CAR constructs were 
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termed: FAP-specific: F19-CD28/CD3, F19--CD28/CD3 or F19-4-1BB/CD3 
and NY-ESO-1-specific: T1-CD28/CD3, T1--CD28/CD3 or T1-4-1BB/CD3 
Retroviral transduction of human peripheral CD3+ T cells was performed as 
previously described (13). Cells were cultured in TCM with 200 IU/ml IL-2 
(Peprotech, NJ, USA), 10ng/ml of both IL-7 and IL-15 (Miltenyi Biotech). After 
transduction, CAR-T cells were rested for 4 days in culture before use in an 
assay. 

Flow cytometry 
Staining for cell surface markers was carried out by incubating with antibodies 
for 30 min on ice. For intracellular stainings, the fixation and permeabilization kit 
from eBioscience was used, as per manufacturer’s instructions. All samples were 
stained with viability dye to exclude dead cells. The samples were measured on a 
FACSCanto II or LSR Fortessa cytometer (BD Biosciences). Data was analyzed 
using FlowJo software (Treestar). For details about staining antibodies, refer to 
supplemental notes. 
 
In vitro functional assays 
Cytotoxicity assays were performed as previously described (16) and as outlined 
in the supplemental notes.  
T-cell proliferation was determined in vitro using bromodeoxyuridine 
(BrdU) APC flow kit (BD Biosciences). Briefly, CAR-T cells were seeded on FAP (R 
and D Systems) coated (2ug/ml) cell culture plates (Thermo Fischer scientific) 
and incubated at 37°C and 5% CO2 for 72 hours followed by addition of BrdU 
(10M) and incubation for another 72 hours. The cells were harvested and 
staining for BrdU was performed as per manufacturer’s instructions followed by 
analysis in a flow cytometer. 
To analyse cytokine release, supernatants of co-cultivated effector and 
target cells were collected after 12 hours of incubation. IFN- and IL-2 levels 
were detected using BD OptEIA human IFN- and human IL-2 ELISA kits, 
respectively, according to the manufacturer’s instruction (BD Biosciences). 
Cytokines IL-2, IL-6, IL-10, IFN- and TNF- from human samples were measured 
using a multiplexed particle-based flow cytometric cytokine assay employing 
cytokine Luminex kits (R&D Systems, Oxon, UK) (17).  
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RNA sequencing  
CD8+ T cells isolated from three buffy donors (N=3) using CD8 microbeads 
(Miltenyi Biotech) were transduced to express F19-CD28/CD3, F19--
CD28/CD3, F19-4-1BB/CD3, T1-CD28/CD3, T1--CD28/CD3 or T1-4-
1BB/CD3 CARs. After transduction, cells were stimulated with recombinant 
human FAP for 6 days and CAR+ T cells were flow sorted on an Aria III cell sorter 
(BD Biosciences). Average 1 X 106 sorted CAR+CD8+ cells with purity > 95% were 
used for RNA extraction using ZymoQuick RNA MicroPrep kit (Lucerna-Chem, 
Luzern, Switzerland) as per manufacturer’s instructions. RNA sequencing was 
performed at the Functional Genomics Center Zurich (FGCZ) and data analyzed 
using Bioconductor EdgeR software package. For detailed description of RNA 
sequencing methods and analysis, refer to supplemental notes. To validate 
sequencing data, redirected T cells produced from healthy donors were 
stimulated with recombinant human FAP for 6 days and expression of 
phenotypic markers was analyzed by flow cytometry. 
 
Humanized mice and adoptive T cell transfer 
Human fetal livers (HFL) were obtained from Advanced Bioscience Resources 
(Alameda, CA, USA). Leukapheresis products were left over from patients which 
initially were allocated autologous CD34+ transplantation but did not need 
further treatment (Department of Oncology, University Hospital Zurich, 
Switzerland). Isolation of CD34+ cells was performed as per the established 
protocol (18) and using CD34 microbeads (Miltenyi Biotech) as per 
manufacturer’s instructions. Purity of CD34 fraction was assessed by FACS and 
the cells were cryopreserved (RPMI + 7.5% DMSO + 20% FBS). NOD-scid IL2Rγnull 
(NSG) mice were obtained from the Jackson Laboratory, and bred and raised 
under specific pathogen-free conditions at the Biologisches Zentrallabor (BZL), 
University Hospital Zurich, Switzerland. For humanization, newborn NSG mice 
received 2×105 or 2×106 CD34+ obtained from HFL or leukapheresis, respectively, 
as per protocol described previously (19) and in Figure S4, A. 
To test survival of redirected T cells, FAP-specific 0.2 X 106 CAR+CD3+ cells  
produced from harvested splenocytes of donor huNSG mice, were intravenously 
injected into recipient huNSG mice (reconstituted with same CD34+ HPCs as 
donor huNSG mice). Persistence of redirected T cells in the blood or abdominal 
organs (at the time of sacrifice) was measured by qPCR. To test the anti-tumor 
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efficacy of redirected T cells, luciferase expressing HT1080FAP tumor cells (0.1 X 
106 cells per mouse) were injected intra-peritoneally (i.p.) in huNSG. Tumor 
development was measured by in vivo bioluminescence imaging using IVIS®200 
Caliper (Caliper Life Sciences, MA, USA) as described previously (11) and based 
on the tumor burden at day 1, mice were equally distributed in groups. This was 
followed by adoptive transfer of redirected T cells i.p. at effector/target (E:T) 
ratio of 4:1 to 8:1. In addition to this, mice were injected intra-peritoneally with 
PD-1 blocking antibody (200g per mouse), every fourth day. Tumor volume was 
measured by bioluminescence as Total Flux (photons/second) and quantified for 
each animal using software Living Image 3.2 (Caliper Life Sciences) as described 
previously (11). Mice were regularly monitored and euthanized when the change 
in body weight exceeded 15% or when they displayed persistent discomfort or 
deviations from normal behaviour.  
 
Quantitative PCR to detect redirected T cells 
Cellular DNA was extracted using DNeasy blood and tissue kit (Qiagen, 
Germany). CAR DNA was quantified by real-time PCR using primers Fwd 5’-
GAAGATGAGCTGCAAGACCA-3’; Rev 5’-GCCCTTGAACTTCTGGTTGT-3’; Probe 5’-
(6FAM)-GTACACCATCCACTGGGTCC-(TAMRA)-3’ and Taqman Universal PCR 
Master Mix (Applied Biosystems, CA, USA). The samples were measured in a 
CFX-384 Touch Real-Time PCR Detection System (Bio-Rad, CA, USA). All samples 
were tested at least in triplicates. 
 
Study Approval and Clinical Trial 
All animal experiments were performed in accordance with the Swiss federal 
and cantonal laws on animal protection (KEK-ZH-Nr. 2011-0498, KVET 10/2013 
and 41/2016). The clinical trial was approved by the cantonal ethics committee 
of Zürich, Switzerland (ethical committee KEK-ZH-Nr. 2012-0106, registered 
under NCT01722149). Informed consent was obtained from the trial subject and 
the trial was conducted in accordance to the principles enunciated in the current 
version of the Declaration of Helsinki (DoH), the Essentials of Good 
Epidemiological Practice issued by Public Health Schweiz (EGEP), the Swiss Law 
and Swiss regulatory authority’s requirements as applicable. The clinical trial for 
the complete recruitment is still ongoing. No primary endpoints are reported 
here. For details on clinical trial design, refer to supplemental notes. 
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RESULTS 
 
Stimulation with anti-CD3/CD28 coated beads lead to enhanced activation and 
reduced expression of senescence marker.  
The ability to expand tumor specific T cells without impairing their 
functional capacity is crucial for the success of adoptive immunotherapies in 
cancer. We investigated the consequences of anti-CD3 and anti-CD28 (CD3/28) 
stimulation provided by beads or antibodies (either in suspension or plate 
coated), on the proliferation, phenotype of T cells and their ability to get 
transduced to express CARs. T cells stimulated with CD3/28 beads or antibodies 
were monitored for several phenotypic markers at different time points (day 0, 
3, 5, 7 and 10) after removal of CD3/28 stimulus (Figure 1A). CD3/28 bead 
stimulation led to increased T cell activation over CD3/28 antibodies, as 
indicated by significantly higher frequencies of CD25+ cells (20). Additionally, 
frequency of CD69+ (early marker of T cell activation), PD-1+ and Ki67bright 
(proliferation marker) cells, was significantly higher in CD3/28 beads stimulated 
cells, immediately after removal of stimulus (day 0). In contrast, frequency of 
CD57+ cells, indicating replicative senescence (21), was significantly less in 
CD3/28 beads activated cells at day 10 after stimulation (Figure 1A). Using CFSE, 
we observed a trend of increased proliferation in T cells stimulated with CD3/28 
beads, which was significantly different from cells that receive no activation 
stimulus (Figure 1B). Besides this, there was no difference in the ability of 
CD3/28 antibody or CD3/28 beads activated T cells to get transduced and 
express CARs (Figure 1C). CAR-T cells activated with CD3/28 beads produced 
significantly higher levels of IL-2 upon antigen-specific stimulation. Nonetheless, 
antigen-specific IFN-secretion remained unaffected (Figure 1D and 1E). These 
findings indicate reduced senescence attributed to lesser frequency of CD57+ 
cells and higher proliferation and expansion potential due to increased 
frequencies of Ki67bright cells and further, higher levels of IL-2 production by CAR-
T cells generated after activation with CD3/28 beads. Thus, we used CD3/28 
beads to produce redirected T cells for further experiments.  
 
Deletion of Lck binding domain in CD28 co-stimulatory moiety provides an 
activated cell-like gene expression profile in redirected T cells upon antigen 
encounter.   
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FAP specific (F19) and control (T1) redirected T cells with the different co-
stimulations CD28/CD3 -CD28/CD3 & 4-1BB/CD3 (Figure S1, A) were 
stimulated with FAP. Firstly, we were interested to identify and compare (fold 
change (Log2FC)) differentially regulated genes in antigen specific over control 
CAR-T cells: F19-CD28/CD3 over T1-CD28/CD3, F19--CD28/CD3 over T1--
CD28/CD3 and F19-4-1BB/CD3 over T1-4-1BB/CD3 (Figure S2, A) to identify 
differences in co-stimulation, which could endow CAR-T cells with improved 
tumor targeting properties, ideal survival and efficacy. -CD28/CD3 co-
stimulation resulted in higher expression of cell cycle genes; indicating enhanced 
proliferation in an antigen-specific manner (Figure 2A (i), genes listed in table 
S1). T cells undergo dynamic metabolic changes during an immune response, 
which can decide their differentiation and fate (22).  We observed that the -
CD2/CD3 co-stimulation resulted in relatively increased expression of genes 
that control cell metabolism such as glycolysis, fatty acid oxidation and oxidative 
phosphorylation (Figure S2, C). Consistent with this observation, the plasma 
membrane transporters which play a predominant role in cell metabolism (22) 
were most distinctly regulated in response to -CD28/CD3 co-stimulation 
(Figure S2, B). We additionally considered key signature markers that distinguish 
effector T-cells from memory T-cells. The expression of genes such as IL-7R, IL-
15, AMPK (PRKAA1, PRKAB2 and PRKAG2), TSC1 (negative regulator of mTOR) 
and SIRT1, which provide a more memory like T-cell phenotype were 
increasingly reduced in -CD28/CD3 co-stimulation (Figure 2A (ii)). Activation 
and proliferation of effector T cells is often accompanied by increased levels of 
inhibitory receptors (20). We found that although -CD28/CD3 co-stimulation 
resulted in enhanced expression of these receptors, e.g. CTLA4, BTLA, ENTPD1 
(CD39) and HAVCR2 (Tim-3), it also demonstrated reduced expression of pre-
apoptotic genes and increased expression of anti-apoptotic genes (Figure 2A 
(iii)). Besides, we observed enhanced upregulation of positive and down-
regulation of negative regulators of autophagy in redirected T cells with -
CD28/CD3 co-stimulation (Figure S2, D). Albeit, the exact relation between 
autophagy and apoptosis is controversial, research evidence indicates that 
autophagy can promote T-cell survival by negatively impacting cell death and 
plays a role in memory formation (23,24). Overall, our sequencing data indicated 
a distinct genetic signature consistent with, highly proliferating, actively 
metabolizing and a terminally differentiated cell like biology of redirected T cells 
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in response to -CD28/CD3 co-stimulation. To further reveal the specific 
transcriptional response to -CD28/CD3 CAR activation, we additionally 
compared the transcriptome of FAP specific -CD28/CD3 CAR expressing T cells 
after antigen stimulation with the other two FAP specific CARs (F19--
CD28/CD3 over F19-CD28/CD3 and F19--CD28/CD3 over F19-4-
1BB/CD3Log2FC of genes identified before and related to cell cycle, 
cytokines, effector or memory phenotype in T-cells was analyzed (Figure 2B). 
Primarily cell cycle genes were higher expressed in -CD28/CD3 CAR expressing 
T cells after antigen encounter in comparison to the 4-1BB/CD3 CAR, while 
these were already constitutively expressed by CD28/CD3 CAR carrying T cells 
without antigen encounter. Further, to validate our findings at the protein level, 
we analyzed the expression of Ki67 (proliferation marker), CD25 (activation 
marker), PD-1 and Tim-3 (activation/exhaustion markers) on FAP specific (F19-
CD28/CD3, F19--CD28/CD3 and F19-4-1BB/CD3) and control (T1-
CD28/CD3, T1--CD28/CD3 and T1-4-1BB/CD3 CAR-T cells after 6 days of 
stimulation with FAP. We observed that proliferation and activation was 
increased in an antigen specific manner in response to -CD28/CD3 than 
CD28/CD3 or 4-1BB/CD3 co-stimulations, as indicated by higher frequencies of 
Ki67bright and CD25+ cells in F19--CD28/CD3 over T1–-CD28/CD3 CAR-T cells 
of CD8+ or CD4+ T cell lineages (Figure 2C). In addition to this, the frequency of 
PD-1+ cells was antigen-specifically enhanced only upon -CD28/CD3 co-
stimulation, while Tim-3 expression was consistently augmented in FAP-specific 
CD28/CD3, -CD28/CD3 and 4-1BB/CD3 CARs over their respective controls. 
There were no remarkable differences observed between FAP-specific 
CD28/CD3 or -CD28/CD3 CAR-T cells, besides both of them being 
significantly distinct from 4-1BB/CD3 CAR in terms of expression of 
activation/exhaustion markers, PD-1 and Tim-3 (Figure 2C). There were no 
differences in the expression of apoptotic markers, Bcl-2 (anti-apoptotic) and 
Bax (pro-apoptotic) at the protein level (Figure S2, E). CAR-T cells demonstrated 
in general, a more central memory and effector memory like phenotype 
compared to non-transduced T cells, irrespective of co-stimulatory signal 
conferred upon antigen binding (Figure S1, B).  
Thus, we confirm that antigen-specific -CD28 co-stimulation provided an 
exceedingly activated cell like profile to redirected T cells, as demonstrated by 
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enhanced frequencies of CD25+, Ki67bright and PD-1+ redirected cells along with 
increased Tim-3 expression. This phenotype was already displayed in part 
without antigen stimulation by CD28/CD3 CAR expressing T cells and never to 
the same extent achieved by 4-1BB/CD3 CAR carrying T cells even after antigen 
stimulation. 
 
Aberrant Lck signaling through the CD28 CAR increases the antigen-specific 
proliferation of redirected T cells.   
Next, we investigated the impact of different co-stimulations on 
proliferation and efficacy of redirected T cells in vitro. Over multiple 
experiments with several donors (n=8) we observed that CD28/CD3 CAR-T cells 
proliferated un-specifically. In contrast, the -CD28/CD3 and 4-1BB/CD3 CAR-
T cells proliferated equally well in a highly antigen-specific manner (Figure 3A). 
Additionally, we observed that the CD8+ CAR-T cells demonstrated significantly 
higher non-specific proliferation compared to CD4+ CAR-T cells (Figure S1, C). 
Notably, all three co-stimulatory CAR constructs demonstrated antigen-specific 
anti-tumor cytotoxicity at different effector/target ratios (Figure 3B). Yet, the 4-
1BB/CD3 CAR showed the least tumor cell lysis which was significantly different 
from the -CD28/CD3 CAR. In addition to this, the frequency of IL-2 and IFN- 
producing CD4+ and CD8+ CAR-T cells was elevated upon cognate antigen 
recognition (Figure 3C and 3D). Likewise, all the three CAR constructs exhibited 
antigen-specific IFN- and IL-2 release (Figure 3E). Even though we observed 
higher frequency of IL-2 producing cells in the 4-1BB/CD3 group (Figure 3C), 
the amount of IL-2 secreted by these cells was very limited (Figure 3E). The 
reduced IL-2 release by the -CD28/CD3 compared to CD28/CD3 CAR-T cells 
has already been reported before (11) and is a consequence of the missing lck 
signal. However, due to its antigen specificity the elevated IL-2 production by 
CD28/CD3 CAR-T cells can only partially explain the observed antigen 
unspecific proliferation. Besides, -CD28/CD3 CAR-T cells revealed maximum 
antigen-specific IFN- release (Figure 3E). Thus, our data demonstrate that T 
cells redirected with -CD28/CD3show less antigen-independent proliferation 
with similar antigen-specific proliferation, similar killing to CD28, and enhanced 
IFNbut reduced IL-2 release.  
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Lck lacking CD28 CAR-T cells show improved tumor control in combination 
with PD-1 blockade in tumor bearing humanized mice. 
We aimed to study the survival and efficacy of redirected T cells in a 
humanized mouse model (huNSG). After comparing human fetal liver (HFL) and 
leukapheresis products as a source for preparing humanized mice we chose HFL 
derived CD34+ cells to reconstitute NSG mice due to significantly higher levels of 
human immune cell engraftment in the peripheral blood (Figure S4, B). We 
found that a very high frequency (~90%) of CD34+ HPCs derived from 
leukapheresis co-expressed CD38 (Figure S4, C), which is a marker for more 
differentiated progenitor cells, thereby correlating with the poor multi-potency 
of these cells.  
To test survival of redirected T cells in humanized mice, we generated CAR 
transduced T cells using splenocytes from humanized mice and injected them 
into recipient mice that were reconstituted from the autologous HPC donor 
(Figure 4A). After adoptive transfer of redirected T cells and serial blood draws 
(Figure 4B), CAR-T cells could be detected in the peripheral blood with almost no 
significant differences between the groups. Up to at least 44 days, redirected T 
cells persisted in the blood of huNSG without any antigenic stimulus (Figure 4C & 
4D). At day 44, we found these cells predominantly in the blood and in highest 
frequency of huNSG mice belonging to 4-1BB/CD3 group (75% mice) compared 
to CD28/CD3 (25% mice) or -CD28/CD3 (40% mice) groups. In addition, we 
found CD28/CD3 redirected T cells in the liver, spleen and BM of 50%, 25% and 
50% of huNSG mice, respectively. -CD28/CD3redirected T cells were observed 
in the BM of 40% huNSG mice and 4-1BB/CD3 CAR-T cells in the liver of 25% of 
huNSG mice (Figure 4E).  
After confirming the survival of redirected T cells, we investigated their 
impact on tumor development in huNSG mice. We injected human fibrosarcoma 
cells expressing FAP (HT1080FAP) in huNSG (Figure 5A). Prior to tumor 
inoculation, the expression of FAP and PD-L1 was confirmed by flow cytometry 
(Figure S3, A). 96% of HT1080FAP tumor cells co-expressed FAP and PD-L1. The 
HT1080FAP tumor cell line is xenogeneic to the murine host and allogeneic to 
the reconstituted human immune compartment of the huNSG. To negate the 
possibility of the reconstituted human immune compartment impacting on the 
tumor development (allogenicity of the tumor cell line towards the host immune 
cells), we examined the correlation of reconstitution frequency (% CD45+ and % 
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CD3+ cells in blood) in huNSG with tumor development (after tumor inoculation 
and prior to injecting redirected T cells). We found that tumor-take in huNSG 
mice was not significantly affected by the level of reconstitution (Figure S4, D). 
The tumor bearing humanized mice were similarly distributed into different 
experimental groups based on reconstitution in blood (% CD45+) and tumor load 
(Figure. S4, E), prior to adoptive transfer of redirected T cells. As described 
previously, we injected tumor in the peritoneal cavity. Due to the strong 
expression of PD-L1 on the tumor cells (Figure S3, A) and a high frequency of 
redirected T cells expressing PD-1 (Figure 2C) the model allows for the testing of 
PD-1 blockade with T cells expressing different CAR constructs. Before transfer, 
there was no in vitro effect of PD-1 blockade with regards to proliferation and 
antigen-specific cell killing by redirected T cells (Figure S3, B & C). After 
implantation of the tumor cells, functionally tested (in vitro) redirected T cells 
(Figure 5B, C & D) were transferred in the peritoneal cavity (in proximity to 
tumor) and PD-1 blocking antibody was administered. Surprisingly, only 
redirected T cells expressing the F19--CD28/CD3CAR induced significantly 
attenuated tumor growth (Figure 5F) and provided an improved survival of mice 
(Figure 5G). FAP expression was confirmed on tumors harvested from mice by 
immunohistochemistry (Figure 5E). No redirected T cells could be measured in 
the peripheral blood (Figure 5H & Figure S5, A). Persistence of redirected T cells 
could be identified in the Tumor Infiltrating Lymphocytes (TILs) and peritoneal 
lavage (Figure 5H). Interestingly, persistence was significantly enhanced in T cells 
redirected by the 4-1BB/CD3 CAR but without anti-tumor efficacy. 
Nevertheless, only the number of redirected T cell with -CD28 co-stimulation 
showed a significant inverse correlation with tumor development (Figure 5I & 
Figure S5, B). Finally, there was no statistically significant difference in frequency 
of Tregs infiltrating tumors between the different CAR groups (Figure S5, C) 
suggesting no prominent role of regulatory T cells for the stronger therapeutic 
effect mediated by the -CD28/CD3 CAR with PD-1 blockade. 
 
First-in-man adoptive transfer of lck lacking CD28 CAR showed persistence of 
redirected T cells up to 21 days. 
Based on our initial data we designed a first-in-human clinical protocol (9) 
for the treatment of MPM patients with FAP-specific redirected T cells and to 
implement FAP-specific redirected T cells as a platform for combination 
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therapies as exemplarily tested in the previously described experiments. In this 
clinical trial, we aimed to use a new application method for the administration of 
redirected T cells supported by our experience from mouse models. Redirected T 
cells were injected in proximity to the malignant cells directly into the pleural 
infusion (Figure 6I). To better characterize the injection site, pleural effusions of 
different patients with MPM were analyzed as first step. Some MPM pleural 
effusions showed prominent levels of TGF-, IL-10 and VEGF suggesting an 
immune suppressive microenvironment (Figure S6). However, these pleural 
effusions did not block in general the antigen-specific release of IFN- when 
compared to cell culture supernatant (Figure 6A). The first patient was treated 
21 days after collection of autologous PBMCs and GMP re-direction of his T cells 
by the F19--CD28/CD3 CAR against FAP (Figure 6B). At the day of transfer, the 
patient’s redirected T cells were also tested ex-vivo (Figure 6D). These cells 
showed antigen-specific release of IFN-, IL-2, IL-10 and TNF-. A biopsy at 6 
months post adoptive transfer confirmed FAP expression mainly in the stroma 
(Figure 6C). Next, the lymphocyte counts, cytokines and the CAR persistence was 
evaluated in the peripheral blood according to the study protocol. Initially, 
lymphocyte counts and cytokines levels (IFN-, IL-2, IL-6, IL-10 and TNF-) 
dropped, followed by an increase of IL-10 at later time points (Figure 6E-G). 
Most interestingly, we observed F19--CD28/CD3 CAR-T cell expansion which 
peaked in the peripheral blood at day 21 post infusion (Figure 6H). The first 
patient of the clinical trial showed stable disease for about 1 year after adoptive 
transfer (Figure 6I). At progression he then received PD-1 blockade for 6 months. 
Thus, the stable disease might have been supported by the CAR-T cell therapy. 
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DISCUSSION 
We previously investigated the therapeutic effect of FAP-specific, 
redirected T cells as an option for treatment of MPM (9,11). Functional T cells 
expressing anti-FAP CARs at high level could be generated by standard 
procedures and these redirected T cells showed antigen-specific activity (11). 
The most recent research in the field of redirected T cells analyzes a multitude 
of different CAR constructs, of which CARs with CD28 or 4-1BB co-stimulation 
are most frequently used. This led us to question, which co-stimulation through 
the CAR should be combined with FAP-specificity for MPM treatment. 
We developed a novel humanized mouse model with autologous 
redirected T cells, thereby avoiding development of GvHD and allogeneic 
rejection of the transferred, redirected T cells. In this model, the used tumor cell 
line is allogeneic to the reconstituted immune compartment of humanized mice. 
However, even a small number of allogeneic tumor cells (0.1 X 106) resulted in a 
reliable tumor take. This result is even more surprising since it is estimated that 
the humanized T cell repertoire contains about 5% alloreactive T cells, which 
had no effect on tumor take (25). Therefore, the effects of redirected T cells do 
not seem to be enhanced by allogeneic endogenous T cells and speaks to the 
low immunogenicity of the tumor cell line.  
We observed improved persistence of autologous redirected T cells in 
humanized mice, considering previously observed survival of up to three weeks 
in NSG mice (13). As expected, the 4-1BB/CD3 CAR performed best with 
regards to persistence until day 44 in the peripheral blood of humanized mice. 
Multiple reasons could be responsible for this observation. Humanized mice 
have low levels of human cytokines, which are essential to support transferred T 
cells. In vitro redirected T cells are dependent on continuous support from 
cytokines like IL-2, IL-7 and IL-15. Some animal models tried to overcome this 
limitation by expressing human cytokines, like IL-7 transgenic NSG mice and, 
therefore, are potential candidate models to further improve the herein 
presented model (26). An alternative explanation for the rather short 
persistence in mice without human immune system reconstitution could be that 
T cells are not supported without antigen stimulation and/or HLA stimulation 
(27). Nevertheless, even in the first patient - who served as the ultimate host for 
his autologous redirected T cells – the CAR-T cells expanded, but persisted no 
longer than 21 days at detectable levels in the peripheral blood.  
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This rather short persistence in humanized mice and man may also be 
explained by the state of the T cells. Due to the process by which redirected T 
cells are produced, the main phenotypes of redirected T cells are effector 
memory or effector phenotype (13). When comparing T cells expressing the -
CD28/CD3CD28/CD3and 4-1BB/CD3 CAR, which had the same phenotype 
after production, differences could be observed regarding gene expression 
profiles induced by antigen stimulation. Previously, the comparison of the CARs 
using CD28 or 4-1BB highlighted the different gene expression profile indicating 
different metabolic programs (28). The authors have shown that CAR-T cells 
with 4-1BB co-stimulation developed more readily a central memory phenotype 
while CD28 co-stimulation yielded effector memory T cells (28). Noteworthy, in 
our experiments, the CD28/CD3 CAR showed unspecific proliferation. Similar 
observation of antigen independent signaling through CD28 co-stimulatory CARs 
was shown before (29) and attributed to certain framework regions in the scFv 
fragments. Another study showed that CD28 CARs may mediate constitutive 
expression of IL-2 and proliferation of T cells (30). Our data indicates that lck 
deletion results in improved antigen-specific proliferation which might be in part 
attributed to less constitutive IL-2 secretion and therefore less tonic signaling. In 
addition, the -CD28/CD3 CAR led to a new and distinct supra-physiological 
gene expression profile in activated CD8+ T cells. It induced the expression of 
gene programs of effector and memory T cells: glycolysis, exhaustion (effector 
programs) and fatty acid oxidation and anti-apoptosis (memory programs). This, 
in theory, advantageous combination did not result in prolonged persistence.  
Nevertheless, in vivo functionality of the redirected T cells could be tested 
with some encouraging results. Only the combination of -CD28/CD3 CAR 
redirected T cells with PD-1 blockade resulted in statistically significant tumor 
control. In contrast, it was shown recently that redirected T cells with CD28 co-
stimulation showed increased in vivo functionality in a mesothelioma model 
using immune-compromised mice (31). We speculate that the different results 
are, in part, attributable to interactions of the humanized immune system and 
the redirected T cells. One potential argument could be clonal competition for 
cytokines, another, increased immune suppression by parts of humanized 
immune system in the tumor microenvironment (e.g. regulatory T cells).  
Previously it has been shown that regional delivery of CAR-T cells vastly 
outperforms systemically infused T cells in mouse models (32). Thus, our line of 
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experimentation and the early clinical trial were focused on the local injection of 
redirected T cells in body cavities harboring the tumor cells (intraperitoneal 
model system in mice and pleural effusion in the clinical trial). Other clinical 
trials have also followed this approach to overcome the issue of T cell trafficking 
(33). Our experimental data indicate that redirected T cells injected into a tumor 
bearing cavity encounter the tumor and cause tumor control. 
Overall, we describe here a first humanized mouse model for autologous 
redirected T cells. We showed that adoptive transfer of FAP-specific redirected T 
cells with a special CAR lacking lck signaling through CD28 co-stimulation, in 
combination with PD-1 blockade induced transient tumor control. Additionally, 
we took this approach from bench to bedside and demonstrate the first clinical 
feasibility of this novel therapeutic concept. Concomitant combinations of PD-1 
blockade and FAP-specific CAR-T cells should be clinically explored in the future. 
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FIGURE LEGENDS 
 
Figure 1. Phenotypic profiling of T cells activated with CD3/28 beads or CD3/28 ab and 
comparison of transduction efficacies.  
CD3+ T cells isolated from buffy donors are incubated with anti-CD3 and anti-CD28 coated 
beads (CD3/28 beads) or anti-CD3 and anti-CD28 antibodies either supplemented in medium 
(CD3/28 ab) or plate bound (CD3/28 plate bound). A Frequency (%) of CD25+, CD57+, CD69+, 
Ki67bright and PD-1+ T-cells are compared at day 0, 3, 5, 7 and 10 after removal of CD3/28 
stimulus. Pooled data from four leucocyte concentrate donors is shown (n=2). B After removal 
of CD3/28 stimulus, T cells are CFSE labelled and frequency (%) of proliferating cells is 
measured at day 2, 4, 6 and 8. C CD3/28 ab or CD3/28 beads stimulated cells are transduced 
to express CD28-CD3 or -CD28/CD3 CARs. Left Panel indicates representative FACS plots 
showing transduction efficacies after CD3/28 beads or CD3/28 ab stimulation. CAR-T cells are 
detected using anti human IgG antibody to stain for CAR receptor; gated huIgG+CD8+ (14% in 
CD3/28 beads and 15% in CD3/28 ab stimulated T cells). Transduction efficacies after CD3/28 
beads or CD3/28 ab activation are compared (right panel) (n=4). D CD8+ cells activated with 
CD3/28 beads or CD3/28 ab are transduced to express F19-CD28/CD3 CAR. Frequency (%) of 
IFN-+and IL-2+ CAR-T cells (by intra-cellular staining) and total IFN-and IL-2 production (by 
ELISA) (E) is compared in response to antigen-specific (+FAP) stimulation or no stimulation (no 
FAP). Representative data from one experiment with two buffy donors is shown (n=2). 
Statistics is done using unpaired t-test. Data is presented as mean ± S.E.M.  
 
 
Figure 2. Transcriptome profiling of redirected T cells and validation of phenotypic markers. 
RNA sequencing was performed using 3 biological replicates. A Differential expression analysis 
indicating log fold change (Log2FC) in gene expression of FAP-specific CAR+CD8+ cells over 
control CAR+CD8+ cells, after stimulation with FAP; CD28/CD3 (F19-CD28/CD3 over T1-
CD28/CD3), -CD28/CD3z (F19--CD28/CD3 over T1--CD28/CD3) and 4-1BB/CD3 (F19-
4-1BB/CD3 over T1-4-1BB/CD3). Heatmaps show differentially regulated genes in (i) Cell 
cycle pathways (525 genes, enlisted in table S1) (ii) effector or memory phenotype in T cells 
and (iii) exhaustion and apoptosis. Color key corresponding to each heat map is presented on 
the upper right corner. Color codes represent Log2FC. B Heatmap showing log fold change 
(Log2FC) of differentially regulated genes in FAP-specific CARs after antigen stimulation; F19-
-CD28/CD3 over F19-CD28/CD3 and F19--CD28/CD3 over F19-4-1BB/CD3. C Expression 
of proliferation marker (Ki67), activation marker (CD25) and immune-checkpoint markers (PD-
1 and Tim-3) was analyzed by FACS in FAP-specific CAR-T cells (F19-CD28/CD3 F19--
CD28/CD3, F19-4-1BB/CD3 and control CAR-T cells (T1-CD28/CD3, T1--CD28/CD3, T1-
4-1BB/CD3 after 6 days of stimulation with antigen (FAP), by comparing the frequencies (%) 
of Ki67bright, CD25+ and PD-1+ CAR-T cells and median fluorescence intensity of Tim-3 on CAR-T 
cells of CD8+ (i) or CD4+ (ii) lineage. Representative plots from one experiment with two 
leucocyte concentrate donors is shown (n=2). Data is presented as mean ± S.E.M. Statistics is 
done using unpaired t-test and p values are indicated.  
 
Figure 3. In vitro functional characterization of redirected T cells with different co-
stimulations.  
CD3+ cells obtained from buffy donors were transduced to express FAP-specific CARs (F19-
CD28/CD3 F19--CD28/CD3, F19-4-1BB/CD3 or control CARs (T1-CD28/CD3, T1--
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CD28/CD3, T1-4-1BB/CD3A Proliferation was compared by culturing CAR transduced cells 
in BrdU supplemented medium and stimulating with (+) or without (-) antigen (FAP). 
Frequency of proliferating cells was determined by first gating on huIgG+ (CAR+) cells followed 
by further selecting BrdU+ cells. Pooled data from 8 buffy donors (n=4) is shown. Statistics is 
done using one way Anova with Tukey’s post test for multiple comparison. B CD3+ CAR-T cells 
were co-cultured with HT1080FAP tumor cells at specified Effector/Target (E:T) ratios and 
tumor cell lysis was measured. Intra-cellular staining was performed to measure the 
frequency (%) of IL-2 (C) and IFN- (D) producing CAR-T cells of CD8 (top panel) or CD4 
(bottom panel) lineage in response to antigen-specific stimulation (+) or no stimulation (-) 
with FAP. E Cytokines IL-2 (top panel) and IFN- (bottom panel) quantified by ELISA in 
supernatant from co-culture of CD3+ CAR-T cells with tumor cells. Representative data from 
one experiment with 2 buffy donors is shown (n=4). P value is calculated using unpaired t-test. 
Data is presented as mean ± S.E.M. 
 
Figure 4. Survival of redirected T cells in humanized mice.  
A Splenocytes were harvested from donor humanized NSG (huNSG) mice and transduced to 
express FAP-specific CARs with different co-stimulations (F19-CD28/CD3, F19--CD28/CD3 
and F19-4-1BB/CD3). Redirected T cells were then injected into recipient huNSG mice. B 
Time line of the adoptive transfer experiment is shown. Redirected T cells were injected 
intravenously at day 0. Blood was drawn at day 2, 8, 14, 24 and 44 after adoptive transfer. 
Mice were sacrificed at day 44 and organs were harvested. C Copies of CAR gene per g of 
DNA in blood at day 2, 8, 14, 24 and 44 as quantified by qPCR. Mean CAR copies 
corresponding to each group and time point are indicated (-) and mentioned (right panel). 
Each circle represents one qPCR replicate (~6 replicates per mouse). Dashed line indicates 
minimum detection threshold.  D Number of mice (Y-axis) that showed positive CAR copies in 
the blood at specified time points (X-axis) in the F19-CD28/CD3 (top), F19--CD28/CD3 
(middle) and F19-4-1BB/CD3 group (bottom). E Copies of CAR gene per g of DNA in blood, 
liver, spleen, lungs and BM of harvested mice at day 44. Each circle illustrates one qPCR 
replicate (~6 replicates per mouse). Mean values are marked (-). Right panel shows number of 
mice (Y-axis) that showed positive CAR copies in corresponding organs in each group (X-axis). 
Representative data from one experiment with 5 mice per group is shown (n=3). 
 
Figure 5. Redirected T cells with -CD28 co-stimulation show better tumor control in 
humanized mice and persistence in tumor infiltrating lymphocytes (TILs) and peritoneal 
lavage (PL).  
A Timeline of adoptive transfer. HT1080FAP cells were injected intra-peritoneally in huNSG 
mice at day 0, followed by measuring tumor in IVIS at day 1. After grouping mice based on 
tumor development, redirected T cells produced from donor matched littermates were 
injected at day 2 at E:T = 4:1 to 8:1. Blood was drawn on day 7, 15 and at the time of sacrifice. 
Tumor measurements were performed at day 1, 8, 13 and 18 post tumor injection. Mice were 
sacrificed based on pre-defined endpoints and the experiment was terminated at day 27. 
Starting from day 2, mice received PD-1 blocking antibody every fourth day. FAP-specific 
redirected T cells produced from donor matched littermates of huNSG, were co-cultivated 
with tumor cells expressing FAP (HT1080FAP) or no FAP (HT1080PA) with or without PD-1 
blocking antibody (anti-PD-1) and B IFN- and C IL-2 release in supernatants and D in vitro 
tumor cell lysis is shown (n=2). P-value calculated using unpaired t-test. E Representative 
tumor section of a mouse stained for FAP (right panel) or secondary antibody control (left 
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panel), original magnification, 400X. F Tumor volume measured in vivo as photons per second 
(in IVIS) at day 1, 8, 13 and 18 was plotted and area under the tumor growth curve (AUC) was 
calculated for each mouse. Top panel shows representative plot from one mouse with AUC 
highlighted in grey. Bottom panel shows comparison of tumor growth measured as AUC. Each 
dot represents the AUC of one mouse. Data is presented as mean ± S.D. P-value is calculated 
using Mann Whitney test. G Percentage of survival of mice is indicated by a Kaplan Meier 
curve. P value is calculated using log rank test. H Copies of CAR gene per g of DNA was 
quantified by qPCR in blood, TILs, PL and spleen of harvested mice (Left panel). Each circle 
indicates one qPCR replicate (total 3 replicates per mouse). Dashed line indicates minimum 
detection threshold. Right panel indicates number of mice (Y-axis) from each group (X-axis) 
that showed positive CAR copies in the corresponding organ. P value is calculated using 
Fischer’s exact test. I Correlation of copies of F19--CD28/CD3 gene in TILs with tumor 
growth (area under the curve). Data is presented as mean ± SEM. Spearman correlation 
coefficient (r) and p value (p) is mentioned. Each dot is one mouse (n = 11). Error bars depicts 
the variation between qPCR replicates. Cumulative data from 3 cohorts of mice in two 
independent experiments is shown (total mice per group = 11). 
 
Figure 6. First-in-man adoptive transfer of lck lacking CD28 CAR showed persistence of 
redirected T cells up to 21 days in peripheral blood.  
 A F19--CD28/CD3 redirected T cells were incubated with HT1080FAP target cell in pleural 
effusions from different donors (1-9) or culture media (R10) and IFN- release was measured 
by ELISA. B Time schedule of the clinical phase-I trial C Biopsy of patient, 6 months after 
adoptive transfer, stained for FAP (original magnification, 400X). D GMP produced, redirected 
FAP-specific T cells were tested in vitro before transfer in different effector to target ratios 
and cytokines were measured. “CAR-“ indicates untransduced T cells. E Absolute counts of 
leukocyte subsets F Percentages of leukocyte subsets G Cytokine levels measured in the 
peripheral blood and H copy numbers of the CAR (F19--CD28/CD3) gene in the peripheral 
blood measured in relation to peripheral blood mononuclear cell (PBMC) DNA amount (per 
g). I CT scan of lungs on different time points with respect to adoptive transfer.  indicates 
the pleural effusion, in which the redirected T cells were injected. 
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